Free Trial

Tempest Therapeutics (TPST) Competitors

Tempest Therapeutics logo
$9.92 +0.07 (+0.71%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$10.32 +0.40 (+4.03%)
As of 08/29/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TPST vs. IMRX, NVCT, ACTU, CRBU, CYBN, MCRB, NKTX, KYTX, BDTX, and GLSI

Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Immuneering (IMRX), Nuvectis Pharma (NVCT), Actuate Therapeutics (ACTU), Caribou Biosciences (CRBU), Cybin (CYBN), Seres Therapeutics (MCRB), Nkarta (NKTX), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry.

Tempest Therapeutics vs. Its Competitors

Immuneering (NASDAQ:IMRX) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Immuneering currently has a consensus target price of $13.00, indicating a potential upside of 126.09%. Tempest Therapeutics has a consensus target price of $30.00, indicating a potential upside of 202.42%. Given Tempest Therapeutics' higher possible upside, analysts plainly believe Tempest Therapeutics is more favorable than Immuneering.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuneering
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Tempest Therapeutics
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

Immuneering's return on equity of -146.28% beat Tempest Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuneeringN/A -146.28% -117.22%
Tempest Therapeutics N/A -334.76%-130.63%

In the previous week, Immuneering had 9 more articles in the media than Tempest Therapeutics. MarketBeat recorded 11 mentions for Immuneering and 2 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.31 beat Immuneering's score of 0.28 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immuneering
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tempest Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Immuneering has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.93, meaning that its stock price is 293% less volatile than the S&P 500.

Tempest Therapeutics has lower revenue, but higher earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immuneering$320K652.63-$61.04M-$1.89-3.04
Tempest TherapeuticsN/AN/A-$41.84M-$14.59-0.68

67.7% of Immuneering shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 22.9% of Immuneering shares are held by insiders. Comparatively, 4.7% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Immuneering beats Tempest Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Tempest Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TPST vs. The Competition

MetricTempest TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$43.74M$2.52B$5.68B$9.86B
Dividend YieldN/A1.67%3.99%4.02%
P/E Ratio-0.6822.8083.1126.58
Price / SalesN/A730.33533.39202.35
Price / CashN/A177.7737.7059.65
Price / Book4.515.9810.576.59
Net Income-$41.84M$32.94M$3.27B$265.83M
7 Day Performance-1.00%-1.28%0.57%0.25%
1 Month Performance31.56%3.54%5.99%3.09%
1 Year Performance-40.85%-3.68%48.91%20.06%

Tempest Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TPST
Tempest Therapeutics
1.9685 of 5 stars
$9.92
+0.7%
$30.00
+202.4%
-43.5%$43.74MN/A-0.6820News Coverage
Positive News
IMRX
Immuneering
3.4717 of 5 stars
$5.95
+21.7%
$13.25
+122.7%
+395.7%$177.60M$320K-3.1560Analyst Forecast
High Trading Volume
NVCT
Nuvectis Pharma
3.4533 of 5 stars
$6.49
-5.5%
$15.33
+136.3%
-3.4%$174.89MN/A0.008
ACTU
Actuate Therapeutics
N/A$7.98
-4.5%
$20.50
+156.9%
+3.8%$173.43MN/A0.0010Trending News
Analyst Forecast
Analyst Revision
CRBU
Caribou Biosciences
2.7674 of 5 stars
$1.88
+1.6%
$6.67
+254.6%
-11.4%$172.28M$9.99M-1.06100
CYBN
Cybin
2.4662 of 5 stars
$7.25
+1.4%
$85.00
+1,072.4%
N/A$171.03MN/A-1.6550High Trading Volume
MCRB
Seres Therapeutics
3.0231 of 5 stars
$19.23
-1.1%
$73.67
+283.1%
+19.9%$170.19M$126.32M-4.18330News Coverage
NKTX
Nkarta
2.0874 of 5 stars
$2.20
-7.2%
$13.60
+518.2%
-61.5%$168.33MN/A-1.49140
KYTX
Kyverna Therapeutics
2.5 of 5 stars
$3.81
-1.0%
$15.60
+309.4%
-53.7%$166.50M$7.03M0.0096News Coverage
Analyst Forecast
Gap Up
BDTX
Black Diamond Therapeutics
3.3301 of 5 stars
$2.87
-1.7%
$12.40
+332.1%
-55.0%$166.25MN/A12.4890Positive News
GLSI
Greenwich LifeSciences
1.7869 of 5 stars
$11.89
-2.4%
$42.00
+253.2%
-19.4%$166.02MN/A-8.743Positive News

Related Companies and Tools


This page (NASDAQ:TPST) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners